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Divalent ions, metabolism abnormalities, and hyper-
parathyroid bone disease noted in patients with chronic
kidney disease (CKD) develop early in the course of
renal insufficiency. In the last two decades, therapy has
focused mostly in treating the bone lesion as well as
controlling the secondary hyperparathyroidism. How-
ever, recent large epidemiologic studies have highlighted
the importance of both hyperphosphatemia and an in-
crease in the calcium burden as major factors leading
to the high mortality rate of end-stage renal disease
(ESRD) patients [1–3]. Furthermore, a recent study
strongly suggests the high mortality rate may be due to
an increase in cardiac events [4]. In the present manu-
script, the causes for the failure of the original therapeu-
tic goals will be discussed first; the changing pattern in
the bone lesions will be assessed second; and third, future
therapeutic approaches will be explored, with special
emphasis in early therapy and avoiding the cardiovascu-
lar abnormalities recently noted in CKD patients.
FAILURE IN ACHIEVING
THERAPEUTIC GOALS
In a recent article, Parfitt [5] has suggested that the
nephrologist has focused more in inhibiting parathyroid
hormone (PTH) secretion rather than preventing the
growth of parathyroid gland hyperplasia. In general,
most nephrologists have commenced vitamin D therapy
in renal patients at a late stage, when the level of PTH
was higher than 3 to 4 times normal levels. In addition,
control of hyperphosphatemia and hypocalcemia, though
a desirable goal, was not considered as important. Until
recently, the available therapeutic agents to achieve the
above mentioned goals were calcitriol (or its analogs)
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and calcium-containing phosphorus binders. However,
abnormalities in the biological markers of secondary hy-
perparathyroidism develop late in the course of CKD;
by this time significant nodular parathyroid hyperplasia
is already present [6]. Thus, it is not surprising that late
therapy often fails and, in addition, an increased burden
of Ca and P (together with a high Ca  P product) may
already be present. Also, late commencement of therapy
means higher doses of calcitriol therapy [7].
CONSEQUENCES OF THE
THERAPEUTIC FAILURE
The most immediate consequence and/or side effect
of current therapy for secondary hyperparathyroidism is
the increase in soft tissue calcification: That is visceral,
periarticular, and, most importantly, cardiovascular. As
it was mentioned earlier there is a high mortality rate in
ESRD patients. A significant positive Ca and P balance is
a significant factor in the morbidity and mortality of
ESRD patients [1]. Thus, patients with serum P concen-
trations 6.5 mg/dL and a Ca  P product 72 mg/dL
have a higher mortality rate (27% and 34%, respectively)
than patients with serum P 6.5 mg/dL and a Ca  P
product 52 mg/dL. Recently, Ganesh et al [4], in a
large dialysis population (12,000 ESRD patients), have
shown that patients with plasma P 6.5 mg/dL have a
56% higher mortality risk mostly due to coronary artery
disease; and a 27% increase risk of sudden death. Fur-
thermore, for each 10 mg/dL increment in the Ca  P
product, there was an 11% increment in sudden death.
Chertow et al [3] has recently evaluated data of 40,000
dialysis patients. The plasma Ca and P of these patients
were analyzed as an independent risk at intervals of 0.5
and 1 mg/dL, respectively. The relative risk was noted
to be the lowest at plasma P concentration between 3
and 5 mg/dL; then there was a progressive increment in
the risk, which was parallel with the increment in plasma
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P concentration. The mortality rate for Ca, taking as
reference concentration of 9 to 9.5 mg/dL, was 0.80 for
plasma Ca 8 mg/dL and 1.47 for a Ca 11 mg/dL.
CLINICAL SIGNS AND SYMPTOMS
OF OSTEODYSTROPHY
First of all, it is necessary to bear in mind that bone
disease in patients with chronic renal failure (CRF) is
usually asymptomatic. Thus, symptoms appear late in
the course of renal osteodystrophy. By the time symp-
toms are present, the patient usually has significant bio-
chemical abnormalities and histologic evidence of bone
disease. The usual symptoms of bone pain, muscular
weakness, periarthritis, and pruritus are usually absent.
However, two clinical syndromes have been increasing
in frequency and deserve some discussion. They are coro-
nary artery calcifications and calciphylaxis.
Recent evidence has shown a high prevalence of coro-
nary artery calcifications in the ESRD population, and
they probably play a major role in the high cardiac mor-
bidity and mortality rates. Indeed, strong relationships
have been found between cardiac deaths and factors that
favor metastatic calcifications (i.e., hyperphosphatemia
and increased Ca PO4 product) [8]. In a large national
study of data from more than 12,000 ESRD patients,
higher mortality rates from coronary artery disease were
found in patients with hyperphosphatemia (serum P6.5
mg/dL) compared to patients with serum P 6.5 mg/dL
(relative risk 1.41; P 0.0005). The risk for sudden death
was also increased in patients with hyperphosphatemia
as well as in patients with elevated Ca  PO4 products
(relative risk 1.07 per 10 mg2/dL2) and those with PTH
levels greater than 495 pg/mL [4]. Calcifications of car-
diac tissue have been reported in nearly 60% of dialysis
patients [9-10]. These are most significant in the coronary
arteries.
Coronary artery calcifications are much more common
and more severe in patients on hemodialysis than in
subjects without renal failure [9-10]. New non-invasive
techniques that utilize the electron-beam computed to-
mography (EBCT) to detect coronary artery calcifica-
tions have illuminated this issue [11–12]. EBCT has high
spatial and temporal resolution, and ultrafast (at subsec-
ond intervals) imaging is triggered by the patient’s EKG
rhythm, which makes it well suited for cardiac imaging.
Calcification of atherosclerotic plaques is found in the
advanced stages of plaque transformation [11]. The ex-
tent of calcification noted by this technique correlates
well with the severity of atherosclerotic lesions detected
by coronary angiography [12]. When compared to coro-
nary angiography as the reference standard, EBCT de-
tected coronary artery disease with a sensitivity of 93%
and a specificity of 73% [12]. Coronary artery calcifica-
tions detected by EBCT were found in the majority of
patients on dialysis [9-10]. Braun et al [10] found that
the incidence of coronary artery calcifications was 2.5-
fold to five times greater in 49 patients on dialysis com-
pared to 102 no dialysis patients of similar age.
Furthermore, these calcifications worsened in the dial-
ysis patients when EBCT studies were repeated one year
later. Goodman et al [13] observed coronary artery calci-
fications to be highly prevalent (14 of 16 patients) in
young adults, aged 20 to 30 years on dialysis, compared
to healthy subjects of the same age (3 of 60 subjects).
Aside from coronary artery calcifications, calcium depos-
its of the valves, especially the mitral and aortic valves,
and of the myocardium are very common. Soft tissue
calcifications may be contributing to conduction abnor-
malities and arrhythmias, left ventricular dysfunction,
aortic and mitral stenosis, ischemia, congestive heart fail-
ure, and death. Most studies have found correlations of
calcifications with uncontrolled hyperphosphatemia, an
increased Ca  PO4 product, and years on dialysis [2–3,
6]. Patients with greater intake of oral calcium had a
higher incidence of coronary artery calcifications [13].
These data suggest that long-term imbalances in cal-
cium (Ca) and phosphorus (P) are factors in the develop-
ment of cardiac calcifications. They also raise the concern
that long-term treatment with high doses of calcium-
based phosphate binders along with inappropriate vita-
min D therapy may contribute to these calcifications.
Vigilant monitoring of serum Ca and P, and Ca  P
product may reduce the incidence of cardiac calcification
and its related morbidity and mortality. Control of serum
Ca and P, and avoidance of excessive Ca intake should
be viewed as part of a comprehensive approach to modify
risk factors for coronary artery disease, which are so
prevalent in the ESRD population [9].
Another serious problem of soft tissue calcification
is calcific uremic arteriolopathy (CUA), also known as
calciphylaxis. These are necrotic skin lesions that usually
present as painful violaceous mottling similar to livedo
reticularis, or as painful nodules or panniculitis. Seyle
[14] first described a syndrome in the experimental ani-
mal in 1962 and postulated that two steps are required to
produce ectopic systemic calcifications. First, a systemic
sensitization induced by agents such as parathyroid hor-
mone (PTH), vitamin D, or a diet high in calcium (Ca)
and phosphorus (P). Second, after a time interval (the
“critical period”), exposure to appropriate challenging
agents by subcutaneous injections resulted in macro-
scopic visible deposits of calcium salts (hydroxyapatite)
systematically and at the site of injection within two to
three days. The challenging agents included local trauma,
iron salt, egg albumin, polymyxin, and glucocorticoids.
Selye named the syndrome “calciphylaxis.” A few years
later, a syndrome characterized by peripheral ischemic
tissular necrosis, vascular calcifications, and cutaneous
ulcerations was reported in uremic patients [15]. Because
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of its resemblance to Selye’s animal model, it was named
“calciphylaxis [15].” However, the syndrome described
in the uremic patient only resembles Selye’s model.
Though a useful concept earlier, the analogy with Selye’s
model may not be warranted because the term “calciphy-
laxis” has pathogenic implications that have not been
confirmed in humans. Thus, significant differences exist
between Selye’s model and uremic calciphylaxis. The
former was characterized by metastatic systemic calcifi-
cations developing after significant invasive manipula-
tions of the animal model, but vascular calcifications
were not present. The latter occurs primarily in the pres-
ence of uremia with abnormalities in divalent ions (i.e.,
PTH, hypercalcemia, and hyperphosphatemia) and most
importantly, vascular calcifications were noted at the
lesions. Retrospectively, it appears that uremic soft tissue
calcification (tumoral calcinosis) is the syndrome most
analogous to Selye’s. It should be emphasized that Sel-
ye’s model did not exhibit the histology consistently de-
scribed with uremic calciphylaxis (i.e., small-vessel calci-
fications and intimal hypertrophy in association with
panniculitis and small-vessel thrombosis) [15].
However, clinically it is important to review certain
pathogenic factors. First, the presence of a uremic milieu
together with a high Ca  P product was noted in the
majority of reports [15–18]. Diffuse vascular calcifica-
tions were frequently noted in the early days of mainte-
nance dialysis [19]. CUA was noted in 20% of dialysis
patients with secondary hyperparathyroidism [19]; it in-
creased to 58% in patients with clinical evidence of hy-
perparathyroidism and to 75% in patients with severe
overt hyperparathyroidism [20]. Still, even in these early
days at a time when secondary hyperparathyroidism was
common, calciphylaxis was uncommon.
Second, the Ca content of the skin was also an impor-
tant pathogenic factor because it was noted to be high
in dialysis patients developing CUA. [21] It also ap-
peared to occur when a very high dialysate Ca concentra-
tion of 4.0 mEq/L was used [22]. In addition, a decrease
in dialysate Ca dramatically improved CUA in some
patients whereas a high dialysate Ca concentration ag-
gravated soft tissue calcification [22]. Furthermore, CUA
was associated with hypercalcemia induced by large oral
doses of calcium carbonate, and it was reversed by dis-
continuing Ca carbonate [23]. It is worth emphasizing
that the use of Ca-containing binders is common, and
that many dialysis patients still ingest large doses of ele-
mental Ca. The long-term effect of this large Ca load
on the dialysis population remains to be established.
It is striking that almost all patients developing CUA
described in recent years were ingesting Ca-containing
binders.
A third important pathogenic factor was the presence
of high PTH levels. Earlier, it appeared that hyperpara-
thyroidism was an important risk factor in the develop-
ment of CUA. [22] Gipstein et al [17] reported a series
of patients with CUA, most with peripheral digital ulcers
in which parathyroidectomy (PTX) resulted in dramatic
healing of the ulcers and total disappearance of the syn-
drome in 61 percent of the patients. A period of marked
hyperphosphatemia was present in each patient at some
time prior to the appearance of CUA. Later, hyperphos-
phatemia was also associated with CUA [19, 24]. In these
patients who had relatively low PTH levels, severe phos-
phorus restriction was shown to reverse CUA [18, 24].
More recently, this syndrome has been noted in pa-
tients with PTH levels close to normal and/or with mini-
mal divalent ion abnormalities, which highlights the
evolving nature of CUA. We recently reported 14 pa-
tients with CUA in whom only 4 (28%) had elevated
PTH levels (870  234 pg/mL) [25]. In the remaining 10
patients, Ca, P, and PTH (250 pg/mL) all appeared to
be well controlled. With the advent of calcitriol (CTR)
and better control of hyperparathyroidism, other factors
have surfaced and become more relevant in the trig-
gering of CUA. As reported by Coates et al [16] and
Bleyer et al [18], the presence of obesity, especially in
white women, is an important predisposing factor to
developing CUA. Morbid obesity was present in 11 of
our 14 patients (79%) with CUA [16]. Supposedly, the
areas rich in adipose tissue may be more prone to small-
vessel damage, which may promote calcifications before
cutaneous lesions and necrosis of the skin become clini-
cally apparent. Coates et al [16] noticed a significant
weight loss preceding the development of the skin lesion
in 7 of 16 patients. Furthermore, Bleyer et al [18] in
a logistic regression analysis identified obesity and low
serum albumin as highly predictive of CUA. Others have
noted an association with insulin-dependent diabetes
mellitus and CUA; however, no mention was made of
obesity. Interestingly, in four patients the lesions devel-
oped in areas that had obviously serve as sites of insulin
injection [18]. Local trauma, such as subcutaneous injec-
tions of heparin or iron dextran, may also be precipitating
factors in the local development of CUA [18].
The relative risk of CUA increased with weight in-
crease. This is important because severe morbid obesity
is uncommon in dialysis patients and these patients may
be easily identified. The impression is that patients with
proximal calciphylaxis have poorer prognoses than those
with acral CUA. Thus, Hafner et al [26] evaluated the
role of PTX in 38 of 58 patients who survived compared
with 13 of 37 patients who did not undergo PTX. Most
importantly, 40 of the 53 patients (75%) with distal loca-
tion of necrosis survived compared with 11 of 42 patients
(26%) with proximal CUA (P  0.00001).
In summary, CUA is a relatively rare but life-threaten-
ing complication in uremic patients. The overall clinical
picture of this syndrome has gradually changed as our
therapeutic approach (discussed later) has changed.
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THE CHANGING PATTERNS OF RENAL
BONE DISEASE
As mentioned above, the therapeutic practice of the
last decade has resulted in a change in the spectrum of
bone disease in the ESRD population. The two common
bone lesions still noted in renal patients include:
High bone turnover disease
This bone lesion is the result of the prevailing high
PTH levels noted in patients with CKD. This lesion still
is present in more than 50% of CKD patients. The persis-
tence of this lesion is due to several factors. Most impor-
tant is the very late commencement of vitamin D therapy,
at a time when parathyroid gland hyperplasia is already
significant. Second, dosing of vitamin D therapy needs to
be appropriate and commensurate with the PTH levels.
Both overtreatment and undertreatment with vitamin D
is not uncommon. Third, the high incidence of hypercal-
cemia and hyperphosphatemia as the result of the late
therapeutic approach with vitamin D has resulted in ces-
sation of therapy, leading to a substantial number of
patients not being treated for a significant secondary
hyperparathyroidism. These patients eventually end up
having surgical intervention (parathyroidectomy), which
in turn will invariably lead to a low bone turnover lesion
[i.e., adynamic bone disease (ABD)].
Low bone turnover disease
This bone lesion is usually associated with low PTH
level. In the past this lesion was noted in ESRD patients
developing aluminum toxicity. Today, despite a decrease
in the use of aluminum-containing P binders, this bone
lesion, ABD, has been described with increasing fre-
quency. The pathophysiology of low bone turnover states
is not well known. This bone lesion is characterized by
low bone volume and it has been steadily increasing in
CKD patients. The most factors associated with the low
PTH levels are the presence of diabetes, advanced age,
and, most importantly, overtreatment with both Ca-con-
taining phosphorus binders and vitamin D.
FUTURE GOALS IN THE THERAPY OF RENAL
BONE DISEASE
Strategies for the future must include (1) prevention of
parathyroid hyperplasia, and (2) avoidance of a positive
balance of Ca and phosphorus (P). Therapy should be
aimed at the early stages of CKD. The data over the
development of parathyroid gland hyperplasia in CKD
patients shows that secondary hyperparathyroidism oc-
curs at early stages of CRF. Martinez at al [27, 28] noted
in 150 patients with various degree of renal insufficiency
an increase in PTH as creatinine clearance decreased to
Fig. 1. A significant decrease in calcitriol suggests that this may be a
factor in the cause of secondary hyperparathyroidism.
60 to 70 mL/min. As can be noted in Figure 1, a signifi-
cant decrease in calcitriol is noted at an earlier stage,
suggesting that the deficit in calcitriol may be a factor
in the cause of secondary hyperparathyroidism. Thus,
this may be the time when therapeutic intervention may
be advisable. However, it is not clear whether the admin-
istration of calcitriol (to correct its deficit) to patients
with CRF may be indicated. The maintenance of physio-
logic levels of calcitriol in patients with renal insufficiency
may not be advisable, since vitamin D therapy in these
patients may result in an increase in the Ca and P burden.
In normal subjects, calcitriol replacement leads to a
marked increased urinary excretion of Ca and P, and
the noted mild deficit of calcitriol in early CRF may be
an adaptive response to protect the kidney from further
renal function deterioration [29]. In this situation, the
administration of vitamin D, by causing a significant in-
crease in intestinal Ca and P absorption, may be harmful.
In patients with creatinine clearances of 50 mL/min, P
restriction results in a decrease in PTH and normaliza-
tion of plasma calcitriol [30–32]. Unfortunately, this ap-
proach is not practical. In addition, the long-term effects
of protein restriction, caused by the phosphate restric-
tion, are not known. A new alternative is the use of a
new vitamin D analog that has minimal effects on gut
absorption of Ca and P. This analog is paricalcitol. Data
is not yet available on the use of paricalcitol in CKD
patients stages 3 and 4. At present, a prospective, double-
blind randomized multicenter study is being conducted
using oral paricalcitol in these patients. The results may
be available next year. Another alternative in CKD,
stage 3 and 4, is the use of P binders. Despite the fact
that most of patients with CKD, stage 3, have normal
serum P, the use of the binders may mimic the results
of dietary P restriction, leading to stimulation of calcitriol
synthesis and suppression of PTH secretion. Unfortu-
nately, at present, studies on the use of safe P binders
to be used in CKD are not available. Furthermore, none
of the available P binders may be safe for therapy in CKD
patients stages 3 and 4. Thus, the use of Ca-containing P
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binders may lead to Ca overload and toxicity, and the
use of a non-Ca binder such as sevelamer promotes an
increment in the protonated amines that may result in
hyperchloremic acidosis.
In ESRD patients, P restriction may directly inhibit
PTH synthesis, but it does not induce any changes in
the levels of calcitriol; by this time, parathyroid gland
hyperplasia is established. At this stage the use of vitamin
D usually induce a positive Ca and P balance with a high
incidence of hypercalcemia and hyperphosphatemia.
The new vitamin D analogs, which inhibit PTH but mini-
mize the hypercalcemic and hyperphosphatemic effects,
may be be indicated.
Rationale for new vitamin D analogs
Substantial evidence has accumulated over the last
number of years showing that it is possible to obtain some
selectivity of the effects of vitamins by the utilization of
vitamin D analogs [33, 34]. The strategy has been to
design a calcitriol analog for its ability to decrease PTH
secretion, and at the same time, to have lesser effects
on the ability to elevate serum Ca and P. The result
would be to correct secondary hyperparathyroidism
while minimizing the toxicity that results from elevations
on serum Ca and P.
A wide variety of vitamin D analogs were screened for
this purpose and include 22-oxa-calcitriol and an analog-
based on the vitamin D2 structure, 19-nor-1,25-dihydroxy-
vitamin D2 (paricalcitol) [35–37]. Later, 1--hydroxy-
vitamin D2 (doxercalciferol) was evaluated for this purpose.
This sterol undergoes 25-hydroxylation in the liver to
form the active metabolite, 1,25-dihydroxyvitamin D2. It
may also enter other metabolic pathways [38]. The use
of the vitamin D2 structure as the basis for the analogs
stems from observations many years ago that vitamin D2
compounds may be less toxic in animals [39]. The use
of vitamin D analogs has also been successfully applied
to many other fields of study. While 1--hydroxyvitamin
D3 is widely used outside the United States, the two
compounds in use in this country include 19-nor-1,25-
dihydroxyvitamin D2 and 1--hydroxyvitamin D2.
Effects of 19-nor-1,25-dihydroxyvitamin
D2 (paricalcitol)
As a result of screening a large number of vitamin
D compounds, paricalcitol was noted to be a potent
suppressor of PTH secretion in vitro, and accordingly
was evaluated extensively in animal models in vivo,
where it was found to be an effective suppressor of PTH
secretion in both normal and uremic animals, and at
the same time, to have a considerably lesser ability to
increase serum calcium or phosphorus than calcitriol
[33–35] in experimental animals in vivo. Thus, while pari-
calcitol had one third the potency of calcitriol in decreas-
ing PTH secretion, it had only one tenth the potency of
calcitriol in terms of its ability to raise serum Ca or P.
Taken together, paricalcitol has a three-fold increase in
selectivity for suppression of PTH compared to the natu-
ral hormone calcitriol. On the basis of these experimental
studies, clinical trials of paricalcitol in ESRD patients
were conducted; they were double blind, randomized,
and multicenter. Paricalcitol was shown to effectively
suppress PTH secretion without the toxic side effects of
elevated Ca and/or P [40, 41]. During these studies, as
well as in studies in experimental animals, it was apparent
that paricalcitol was not totally devoid of a hypercalcemic
effect, and overtreatment may result in hypercalcemia
[41, 42]. The few episodes of hypercalcemia occurred
when intact PTH values were suppressed to near 100
pg/mL, levels that are considered to be undesirably low.
The long-term effects of paricalcitol have also shown
the absence of hypercalcemia in longer-term studies in
ESRD patients [23–42]. Therefore, it is important to
emphasize that vitamin D analogs, like paricalcitol,
should not be considered non-calcemic vitamin D ana-
logs, but rather, be considered to have less calcemic
activity than the native hormone. Studies by Lerma et al
[43] have evaluated the relative effects of these com-
pounds on hyperphosphatemia in patients and found,
during a comparative trial, that paricalcitol was associ-
ated with fewer episodes of hyperphosphatemia at all
phases of the study than calcitriol. Recently, a double-
blind randomized multicenter study comparing the safety
and effectiveness of intravenous paricalcitol and calcitriol
in suppressing PTH concentration in hemodialysis pa-
tients has been reported [44]. A total of 263 randomized
patients from national and international sites were en-
rolled. Paricalcitol-treated patients achieved a 50% re-
duction in PTH values faster than calcitriol treated pa-
tients (P  0.02). Most importantly, paricalcitol-treated
patients had significantly fewer sustained episodes of
hypercalcemia and/or increased Ca  P product than
calcitriol patients (P  0.008). These clinical studies are
again consistent with the effects noted in experimental
uremic animals. Thus, it appears that from a variety of
studies in experimental animals and in patients, paricalci-
tol is an effective agent for the suppression of secondary
hyperparathyroidism in ESRD patients, and because of
its lesser ability to raise serum calcium and phosphorus
than the parent compound, calcitriol, it provides a wider
therapeutic window for the control of hyperparathyroid-
ism in this patient group.
Effects of 1-dihydroxyvitamin D2 (doxercalciferol)
This vitamin D analog has been recently introduced
in this country for the control of hyperparathyroidism
in ESRD patients. As discussed above, interest in the
vitamin D2 compounds arose because of observations by
Sjogen et al [39], which indicated that while vitamin D2
and vitamin D3 sterols were equally effective in curing
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rickets in experimental animals, and had similar effects
on calcium transport in the intestine and on phosphate
uptake, it appeared that the D2 compounds were less
toxic in small groups of experimental animals receiving
very large doses of either 1--hydroxyvitamin D2 or
1--hydroxyvitamin D3. In this study, there was a higher
mortality in the group receiving doses of 5 to 20 g/
kg/day of 1--hydroxyvitamin D3 compared with those
receiving or 1--hydroxyvitamin D2. The reason for the
greater toxicity of the 1--hydroxyvitamin D3 groups was
not apparent from these studies, since the increment in
serum calcium appeared to be similar with D2- and D3-
based compounds, as were the effects on intestinal cal-
cium transport [39]. Similar studies subsequently have
re-evaluated differences in serum Ca and P between
these two compounds in the ovariectomized rat model.
The effects of both compounds on the ability to elevate
serum Ca and P and to decrease levels in intact PTH
were identical [45]. Thus, from the results obtained in
experimental animals, the vitamin D2-based sterol ap-
pears to have equal potency compared to the D3 counter-
part, in terms of suppression of PTH, increasing Ca ab-
sorption from the intestine, and elevating serum P.
Recently, the effects of doxercalciferol and paricalcitol
on serum Ca, P, and Ca P product has been compared
in the experimental uremic animal. While doxercalciferol
has a significant increment in Ca, P, and Ca  P product
(similar to calcitriol), paricalcitol did not [46]. Thus, there
appears to be no evidence for selectivity for PTH sup-
pression with this compound at the present time. Doxer-
calciferol has been administered successfully to ESRD
patients with, and initially utilized in an oral form, was
found to be effective in decreasing PTH [47]. Subse-
quently, it was also introduced in intravenous form, and
more extensive studies have shown that both oral and
intravenous forms were effective in decreasing PTH se-
cretion [48, 49]. However, there tended to be higher
serum Ca values with the oral compound than with the
intravenous, and serum P values appeared to be higher
than with the intravenous compounds. Overall, between
8% to 15% of all determinations for serum Ca were in
the hypercalcemic range for intravenous and oral treat-
ments, respectively, and between 14% and 17% samples
were associated with hyperphosphatemia greater than
6.9 mg/dL [30]. These data reveal a substantial number
of episodes of hypercalcemia and hyperphosphatemia
with this treatment.
Calcimimetics
A new novel approach to decrease PTH secretion and
control secondary hyperparathyroidism is through the
stimulation of the calcium sensing receptor (CaR) in the
parathyroid gland by new agents that mimic the effect of
blood ionized Ca; these are the so-called calcimimetics.
Early studies showed that calcimimetics are potent inhib-
itors of PTH secretion with rapid onset of action, over
minutes to hours. Recent multicenter randomized stud-
ies have shown that a new generation of calcimimetics,
AMG 073 (cinacalcet), in hemodialysis patients effec-
tively suppresses PTH levels without inducing hypercal-
cemia or hyperphosphatemia. In fact, treatment with
cinacalcet resulted in a significant decrease of Ca  P
product. Thus, this compound, by directly targeting CaR
in the parathyroid gland, may provide an alternative
and/or an adjunct to vitamin D therapy in ESRD patients
with secondary hyperparathyroidism and permit further
suppression of PTH without increases in serum Ca or
worsening of the hyperphosphatemia. Long-term studies
evaluating cinacalcet therapy and follow-up are needed
to determine if this compound(s) improves survival and
the quality of life of ESRD patients.
Reprint requests to Francisco Llach, M.D., Georgetown University
Hospital, 6th Floor PHC, Suite 6003, Washington, DC 20007.
E-mail: fllach@pol.net
REFERENCES
1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Associa-
tion of serum phosphorus and calcium x phosphate product with
mortality risk in chronic hemodialysis patients: A national study.
Am J Kidney Dis Vol 31:607–617, 1998
2. Levin NH-S, Strawderman RL, Port FK: Which causes of death
are related to hyperphosphatemia in hemodialysis patients. J Am
Soc Nephrol 9: 217 A; 1998
3. Chertow GM, Lowrie EG, Lew NL, Lazarus JM: J Am Soc
Nephrol 11:560, 2000
4. Ganesh SK, Stack AG, Levin NW, et al: Association of elevated
serum PO(4), Ca x PO(4) product, and parathyroid hormone with
cardiac mortality risk in chronic hemodialysis patients. J Am Soc
Nephrol 12(10):2131–2138, 2001
5. Parffit AM: The hyperparathyroidism of chronic renal failure: A
disorder of growth. Kidney Int 52(1):3–9, 1997
6. Hsu CH: Are we mismanaging calcium and phosphate metabolism
in renal failure? Am J Kidney Dis 29:641–649, 1997
7. Ferna´ndez E, Llach F: Guidelines for dosing of intravenous
calcitriol in dialysis patients with hyperparathyroidism. Nephrol
Dial Transplant 11(Suppl 3):96–101, 1996
8. Llach F: Calcification: Dealing with another risk factor in patients
with renal failure. Semin Dial 12:293–295, 1999
9. Ribeiro S, Ramos A, Brandero A, et al: Cardiac valve calcification
in hemodialysis patients: Role of calcium-phosphate metabolism.
Nephrol Dial Transplant 13:2037–2040, 1998
10. Braun J, Olendorf M, Moshage W, et al: Electron beam com-
puted tomography in the evaluation of cardiac calcification in
chronic dialysis patients. Am J Kidney Dis 27:394–401, 1996
11. Agatston AS, Janowitz WR, Hildner FJ, et al: Quantification
of coronary artery calcium using ultrafast computed tomography.
J Am Coll Cardiol 15:827–832, 1990
12. Achenback S, Moshage W, Rogers D, et al: Value of electron-
beam computed tomography for the noninvasive detection of high-
grade coronary artery stenoses and occlusions. N Engl J Med 339:
1964–1971, 1998
13. Goodman WG, Goldin J, Kuzon BD, et al: Coronary artery calci-
fication in young adults with ESRD who are undergoing dialysis.
N Engl J Med 342:1478–1483, 2000
14. Selye H: Calciphylaxis. Chicago, IL, University of Chicago Press,
1962
15. Anderson DC, Stewart WK, Piercy DM: Calcifying panniculitis
with fat and skin necrosis in a case of uremia with autonomous
hyperparathyroidism. Lancet 2:323–325, 1968
16. Coates T, Kirkland GS, Dymock RB, et al: Ischemic tissue necro-
Llach and Ferna´ndez: Overview of renal bone disease S-119
sis (calciphylaxis) in renal failure. Am J Kidney Dis 32:384–391,
1998
17. Gipstein RM, Coburn JW, Adams DA, et al: Calciphylaxis in man.
Arch Intern Med 136:1273–1280, 1976
18. Bleyer AJ, Choi M, Igwenezie B, et al: A case control study of
proximal calciphylaxis. Am J Kidney Dis 32:376–383, 1998
19. Katz AL, Hampers CL, Merrill JP: Seconday hyperparathyroid-
ism and renal osteodystrophy in chronic renal failure: Analysis of
195 patients, with observations on the effects of chronic dialysis,
kidney transplantation and subtotal parathyroidectomy. Medicine
(Baltimore) 48:333–374, 1969
20. Ross CN, Casidy MJD, Thompson M, et al: Proximal cutaneous
necrosis associated with small vessel calcification in renal failure.
Q J Med 289:443–450, 1991
21. Massry SG, Coburn JW, Hartenbower DL, et al: Mineral content
of human skin in uremia. Effect of secondary hyperparathroidism
and hemodialysis. Proc Eur Dial Transplant Assoc 7:146–148, 1970
22. Massry SG, Coburn JW, Hartenbower DL, et al: The effect of
calcemic disorders and uremia or the mineral content of the skin.
Isr J Med Sci 7:514–517, 1971
23. Campistol JM, Almirall J, Martin E, et al: Calcium-carbonate-
induced calciphylaxis. Nephrol 51:549–550, 1989
24. McAuley K, Devereux F, Walker R: Calciphylaxis in two non-
compliant patients with end-stage renal failure. Nephrol Dial
Transplant 12:1061–1063, 1997
25. Llach F, Goldblat M, Freundlich RE, et al: The evolving pattern
of calcific uremic arteriolopathy (calciphylaxis). J Am Soc Nephrol
2000
26. Hafner J, Keusch G, Wahl C, et al: uremic small artery disease
with medical calcification and intimal hypertrophy (so-called calci-
phylaxis): A complication of chronic renal failure and benefit from
parathyroidectomy. J Am Acad Dermatol 33:954–962, 1995
27. Martinez I, Saracho R, Montenegro J, Llach F: The importance
of dietary calcium and phoshorus in the secondary hyperparathy-
roidism of patients with early renal failure. Am J Kidney Dis
29(4):496–502, 1997
28. Martinez I, Saracho R, Montenegro J, Llach F: A deficit of
calcitriol may not be the initial factor in the pathogenesis of second-
ary hyperparathyroidism. Nephrol Dial Transplant 11:22–28, 1996
29. Hsu CH, Patel SR,Young EW, Vanholder R: The biological
action of calcitriol in renal failure. Kidney Int 46(3):605–612, 1994
30. Portale AA, Halloran BP, Morris RC Jr: Physiologic regulation
of the serum concentration of 1,25-dihydroxyvitamin D by phos-
phorus in normal men. J Clin Invest 83(5):1494–1499, 1989
31. Amor J, Areste N, Cambil T, et al: Effects of dietary phosphorus
restriction on the production of 1,25(OH)2D3 (calcitriol) in pa-
tients with moderated renal failure. Nefrologia 20(2):158–163, 2000.
32. Llach F, Massry SG: On the mechanism of secondary hyperpara-
thyroidism in moderate renal insufficiency. J Clin Endocrinol
Metab 61:601–606, 1985
33. Brown AJ, Finch JL, Lopez-Hilker S, et al: New active analogues
of vitamin D with low calcemic activity. Kidney Int (Suppl 29):S22–
S27, 1990
34. Brown AJ, Dusso A, Slatopolsky E: Selective vitamin D analogs
and their therapeutic applications. Semin Nephrol 14:156–174, 1994
35. Takahashi F, Finch JL, Denda M, et al: A new analog of 1,25-
(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and
parathyroid gland growth in uremic rats without elevation of intes-
tinal vitamin D receptor content. Am J Kidney Dis 30:105–112,
1997
36. Slatopolsky E, Finch J, Ritter C, et al: A new analog of calcitriol,
19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion
in uremic rats in the absence of hypercalcemia. Am J Kidney Dis
26:852–860, 1995
37. Finch JL, Brown AJ, Slatopolsky E: Differential effects of 19-
nor-1,25-(OH)2 D2 on calcium and phosphate resorption in bone.
J Am Soc Nephrol 10:980–985, 1999
38. Mawer EB, Jones G, Davies M, et al: Unique 24-hydroxylated
metabolites represent a significant pathway of metabolism of vita-
min D2 in humans: 24-hydroxyvitamin D2 and 1,24- dihydroxyvita-
min D2 detectable in human serum. J Clin Endocrinol Metab
83:2156–2166, 1998
39. Sjogen G, Smith C, Lindgren U, DeLuca HF: 1 alpha-Hydroxy-
vitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the
rat. Proc Soc Exp Biol Med 178:432–436, 1985
40. Llach F, Keshav G, Goldblat MV, et al: Suppression of parathy-
roid hormone secretion in hemodialysis patients by a novel vitamin
D analog: 19-nor-1-alpha-25dihydroxyvitamin D2 (Paricalcitol)
Am J Kidney Dis S48–S54, 1998
41. Martin KJ, Gonzalez EA, Gellens M, et al: 19-nor-1--25-dihy-
droxyvitamin D2 (paricalcitol) safely and effectively reduces the
levels of intact PTH in patients on hemodialysis. J Am Soc Nephrol
10:1427–1432, 1998
42. Llach F, Yudd M: Paricalcitol in dialysis patients with calcitriol
resistant secondary hyperparathyroidism. Am J Kidney Dis 38:S45–
S50, 2001
43. Lerma EV, DPM, Ghanekar HP, et al: A comparative study be-
tween 19-nor-1-alpha–25-dihydroxyvitamin D2 and intravenous
calcitriol on PTH suppression in hemodialysis patients. J Am Soc
Nephrol 11:578A, 2000
44. Sprague SM, Llach F, Amdhal M, et al: Paricalcitol versus
calcitriol in the treatmen of secondary hyperparathyroidism. Kid-
ney Int 63:1483–1490, 2003
45. Weber K, Goldberg M, Stangassinger M, Erben RG: 1alpha-
hydroxyvitamin D2 is less toxic but not bone selective relative to
1alpha-hydroxyvitamin D3 in ovariectomized rats. J Bone Miner
Res 16:639–651, 2001
46. Slatopolsky E, Cozzolino M, Finch J: Differential effects of 19-
nor-1,25(OH)2D2 (19-nor)and 1-(OH)D2 (1 D2) on calcium and
phosphorus metabolism in rats. J Am Soc Nephrol 12:773A, 2001
47. Tan AU, Jr, Levine BS, Mazess RB, et al: Effective suppression
of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodi-
alysis patients with moderate to severe secondary hyperparathy-
roidism. Kidney Int 51:317–323, 1997
48. Frazao JM, Elangovan L, Maung HM, et al: Intermittent doxer-
calciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hy-
perparathyroidism. Am J Kidney Dis 36:550–561, 2000
49. Maung HM, Elangovan L, Frazao JM, et al: Efficacy and side
effects of intermittent intravenous and oral doxercalciferol
(1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary
hyperparathyroidism: A sequential comparison. Am J Kidney Dis
37:532–543, 2001
